A detailed history of Intellectus Partners, LLC transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Intellectus Partners, LLC holds 58,825 shares of NTLA stock, worth $829,432. This represents 0.32% of its overall portfolio holdings.

Number of Shares
58,825
Previous 58,225 1.03%
Holding current value
$829,432
Previous $1.3 Million 7.29%
% of portfolio
0.32%
Previous 0.36%

Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 06, 2024

BUY
$19.72 - $27.36 $11,832 - $16,416
600 Added 1.03%
58,825 $1.21 Million
Q2 2024

Jul 18, 2024

BUY
$20.02 - $27.22 $24,524 - $33,344
1,225 Added 2.15%
58,225 $1.3 Million
Q1 2024

May 03, 2024

BUY
$23.82 - $32.8 $32,157 - $44,279
1,350 Added 2.43%
57,000 $1.57 Million
Q4 2023

Feb 05, 2024

BUY
$23.16 - $32.34 $113,484 - $158,466
4,900 Added 9.66%
55,650 $1.7 Million
Q3 2023

Oct 25, 2023

SELL
$31.62 - $45.78 $20,553 - $29,757
-650 Reduced 1.26%
50,750 $1.6 Million
Q2 2023

Jul 31, 2023

BUY
$34.58 - $46.03 $177,568 - $236,364
5,135 Added 11.1%
51,400 $2.1 Million
Q1 2023

May 04, 2023

BUY
$33.3 - $44.82 $19,980 - $26,892
600 Added 1.31%
46,265 $1.72 Million
Q4 2022

Feb 02, 2023

BUY
$33.21 - $62.69 $122,877 - $231,953
3,700 Added 8.82%
45,665 $1.59 Million
Q3 2022

Nov 14, 2022

SELL
$53.92 - $71.7 $67,939 - $90,342
-1,260 Reduced 2.91%
41,965 $2.35 Million
Q2 2022

Aug 12, 2022

SELL
$38.49 - $76.21 $47,150 - $93,357
-1,225 Reduced 2.76%
43,225 $2.24 Million
Q1 2022

May 16, 2022

SELL
$58.27 - $118.99 $179,180 - $365,894
-3,075 Reduced 6.47%
44,450 $3.23 Million
Q4 2021

Feb 14, 2022

SELL
$100.76 - $138.36 $345,103 - $473,883
-3,425 Reduced 6.72%
47,525 $5.62 Million
Q3 2021

Nov 16, 2021

BUY
$132.37 - $176.78 $304,451 - $406,594
2,300 Added 4.73%
50,950 $6.84 Million
Q2 2021

Aug 13, 2021

SELL
$60.88 - $161.91 $1.4 Million - $3.72 Million
-22,975 Reduced 32.08%
48,650 $7.88 Million
Q1 2021

May 17, 2021

BUY
$46.59 - $83.68 $265,563 - $476,976
5,700 Added 8.65%
71,625 $4.61 Million
Q4 2020

Feb 18, 2021

BUY
$18.83 - $63.53 $1.23 Million - $4.15 Million
65,275 Added 10042.31%
65,925 $3.59 Million
Q4 2020

Feb 12, 2021

SELL
$18.83 - $63.53 $847,349 - $2.86 Million
-45,000 Reduced 98.58%
650 $3.59 Million
Q3 2020

Nov 16, 2020

BUY
$17.47 - $24.93 $797,505 - $1.14 Million
45,650 New
45,650 $908,000

Others Institutions Holding NTLA

About Intellia Therapeutics, Inc.


  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $1.07B
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Intellectus Partners, LLC Portfolio

Follow Intellectus Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Intellectus Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Intellectus Partners, LLC with notifications on news.